



**ASX ANNOUNCEMENT**

**7 January 2010**

**Human Trial of VitroGro®:  
Prof. Keith Harding, Cardiff University**

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced today that a contract has been executed with Cardiff University where Prof. Keith Harding will conduct the human trial of VitroGro® planned for completion at the end of 2010.

This clinical trial will be used to produce the final data necessary for approval of VitroGro® for sale, initially in Europe, Canada, Australia and New Zealand.

The CEO of Tissue Therapies, Dr Steven Mercer said, "We are delighted to have this agreement in place and for Prof. Harding to act as the Lead Principal Investigator for this important human trial of VitroGro®."

"Professor Harding is widely recognised as one of the most eminent wound healing physicians and researchers in the world today. His expertise and that of his whole team will be invaluable to Tissue Therapies for this human trial."

Dr Mercer went on to say, "This essential part of the commercialisation plan for the sale of VitroGro® wound healing products is now in place, on schedule."

Further information:

Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: +61 (0)7 3839 9938

Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

## **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute of Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic skin ulcers and burns.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)